Pages that link to "Q35551107"
Jump to navigation
Jump to search
The following pages link to Epigenetic targets for immune intervention in human malignancies (Q35551107):
Displaying 31 items.
- Generation of a genomic tiling array of the human major histocompatibility complex (MHC) and its application for DNA methylation analysis (Q24288913) (← links)
- Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid (Q24288944) (← links)
- Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes (Q24540025) (← links)
- Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer (Q33715446) (← links)
- Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy (Q33957165) (← links)
- Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects (Q34502475) (← links)
- Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study (Q34839826) (← links)
- The prognostic value of global DNA hypomethylation in cancer: a meta-analysis (Q35237505) (← links)
- Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 (Q35556061) (← links)
- The silence of the genes: epigenetic disturbances in haematopoietic malignancies (Q36066276) (← links)
- Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. (Q36338026) (← links)
- MHC class I antigens and immune surveillance in transformed cells. (Q36714774) (← links)
- Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. (Q36801625) (← links)
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance (Q37287152) (← links)
- The biology of cancer testis antigens: putative function, regulation and therapeutic potential (Q37849976) (← links)
- Decitabine: a promising epi-immunotherapeutic agent in solid tumors (Q38314204) (← links)
- Improving cancer immunotherapy with DNA methyltransferase inhibitors. (Q38662760) (← links)
- Marked for death: targeting epigenetic changes in cancer (Q38747872) (← links)
- Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines (Q38981497) (← links)
- HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. (Q39211999) (← links)
- RANKL Expression Specifically Observed in Vivo Promotes Epithelial Mesenchymal Transition and Tumor Progression (Q39544703) (← links)
- Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy (Q39586718) (← links)
- p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia (Q39916396) (← links)
- Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b (Q40277144) (← links)
- The MMA1 gene family of cancer-testis antigens has multiple alternative splice variants: characterization of their expression profile, the genomic organization, and transcript properties (Q40506423) (← links)
- Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. (Q40511605) (← links)
- Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma (Q41550137) (← links)
- HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. (Q46017171) (← links)
- Epigenetic Mechanisms in Cancer Formation and Progression (Q57570317) (← links)
- Epigenetically regulated tumor-associated antigens in melanoma (Q57570339) (← links)
- Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study (Q64069792) (← links)